Fig 4. Enhanced cytotoxicity of the combinations ofterpinen-4-ol and different conventional chemotherapy approaches.

1x10⁴ CR DLD1 cells (A,B), and pancreatic MIA-PACA (C,D) and Panc-1 (E,F) cells were seeded in 96-well plates in complete medium. On the next day, oxaliplatin at a concentration of 0.2μM and terpinen-4-ol at a concentration of 0.01% (A), 5-FU at a concentration of 0.3μM and terpinen-4-ol at a concentration of 0.01% (B), gemcitabine at a concentration of 0.1μM and terpinen-4-ol at a concentration of 0.01%, (C) gemcitabine at a concentration of 0.1μM, erlotinib hydrochlorides (Tarceva^®) at a concentration of 0.1μM, and terpinen-4-ol at a concentration of 0.01% (D), gemcitabine at a concentration of 1μM and terpinen-4-ol at a concentration of 0.01% (E), gemcitabine at a concentration of 1μM, anderlotinib hydrochlorides (Tarceva^®) at a concentration of 0.1μM, and terpinen-4-ol at a concentration of 0.01% (F) were added for 72 h. Cell survival was evaluated by the enzymatic MTT assay. Each bar represents the mean±SD of a set of data determined in triplicates. *P < .05, **P < .05